Wegovy maker Novo hit with investor class action over revenue forecast cut

Novo Nordisk, producer of the weight-loss drug Wegovy, is facing a proposed class-action lawsuit in U.S. federal court from investors alleging the company issued misleadingly optimistic growth forecasts and downplayed competitive risks in the obesity market. This legal action follows a recent $70 billion decline in Novo's market value after the company lowered its 2025 sales and operating profit outlook for Wegovy and Ozempic, citing persistent use of compounded versions and slower-than-expected market expansion. The lawsuit covers investors who purchased stock between May 7, 2025, and July 28.

Analysis

Novo Nordisk is facing significant legal and financial headwinds following a downward revision of its 2025 sales and operating profit outlook for its key drugs, Wegovy and Ozempic. The proposed class-action lawsuit alleges the company misled investors by maintaining optimistic forecasts while understating competitive risks, a claim that gained traction after a single-day $70 billion erosion of its market capitalization. Management attributes the guidance cut to three primary factors: persistent competition from cheaper, compounded versions of semaglutide, broader competitive pressures, and a slower-than-expected expansion of the obesity market. The ongoing availability of compounded alternatives, initially permitted by the FDA during a supply shortage, appears to be a more durable threat than anticipated, directly impacting Wegovy's growth trajectory in the crucial U.S. market. This pressure is further exemplified by the public and acrimonious termination of its partnership with telehealth firm Hims & Hers, signaling deepening friction over the sale of unapproved drug versions and adding a layer of reputational and operational risk.

Key Decisions for Investors

• Investors should closely monitor updates on the class-action lawsuit and the FDA's stance on compounded semaglutide, as these legal and regulatory developments pose a direct risk to Novo's revenue streams and could result in financial penalties.
• The lowered guidance necessitates a re-evaluation of valuation models for Novo Nordisk, specifically by adjusting forward-looking growth assumptions for Wegovy to reflect increased competition and a potentially slower market adoption rate.
• Given the stated reasons for the guidance cut, it is critical to scrutinize sales data from the U.S. market for signs of stabilization or further deterioration against both branded and compounded competitors before considering new or expanded positions.
• The conflict with Hims & Hers highlights channel and partner risks; therefore, investors should assess the stability and compliance of Novo's other distribution partnerships to gauge potential for further disruptions.